Litigation Details for Biogen Inc. v. Teva Pharmaceuticals Development Inc. (D. Del. 2021)
✉ Email this page to a colleague
Biogen Inc. v. Teva Pharmaceuticals Development Inc. (D. Del. 2021)
| Docket | ⤷ Sign Up | Date Filed | 2021-03-17 |
| Court | District Court, D. Delaware | Date Terminated | 2021-10-08 |
| Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | None | Referred To | |
| Parties | ALKERMES PHARMA IRELAND LIMITED | ||
| Patents | 10,080,733; 8,669,281; 9,090,558 | ||
| Attorneys | Jeremy A. Tigan | ||
| Firms | Morris, Nichols, Arsht & Tunnell | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Biogen Inc. v. Teva Pharmaceuticals Development Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Biogen Inc. v. Teva Pharmaceuticals Development Inc. (D. Del. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2021-03-17 | 1 | Complaint | U.S. Patent Nos. 8,669,281 (“the ’281 patent”); 9,090,558 (“the ’558 patent”); and 10,080,733 (“the … 1. This is an action for patent infringement under the patent laws of the United States, Title…the ’733 patent”) (collectively “the Asserted Patents”). Teva notified Plaintiffs that it had submitted…Asserted Patents in the event that Teva’s ANDA Product is approved before the Asserted Patents expire.…assignee of the ’281 patent. 19. BSM is the exclusive licensee of the ’281 patent. 20. | External link to document |
| 2021-03-17 | 4 | Patent/Trademark Report to Commissioner of Patents | Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,669,281 ;9,090,558 ;10,080,733. (mal) …2021 8 October 2021 1:21-cv-00389 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
